09/28/23 7:00 AMNasdaq : CMMB conferenceslow floatChemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities ConferenceChemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet...RHEA-AIpositive
08/14/23 8:00 AMNasdaq : CMMB earningslow floatChemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateChemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today...RHEA-AIneutral
06/28/23 7:00 AMNasdaq : CMMB low floatChemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing CholangitisChemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high...RHEA-AIneutral
06/26/23 7:00 AMNasdaq : CMMB low floatChemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023Chemomab Therapeutics Ltd.,, a...RHEA-AIneutral
06/21/23 7:00 AMNasdaq : CMMB clinical triallow floatChemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023Chemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported...RHEA-AIpositive
06/05/23 7:00 AMNasdaq : CMMB managementlow floatChemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate UpdateChemomab Therapeutics Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...RHEA-AIpositive
06/02/23 9:00 AMNasdaq : CMMB low floatPatient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic SclerosisChemomab Therapeutics Ltd., a clinical stage biotechnology company...RHEA-AIneutral
05/24/23 7:00 AMNasdaq : CMMB conferenceslow floatChemomab Therapeutics to Participate in Upcoming Scientific ConferencesEASL Congress 2023– Vienna, Austria, June 21-24, 2023. EASL Congress 2023– Vienna, Austria, June 21-24, 2023. EASL Congress 2023– Vienna, Austria, June 21-24, 2023.RHEA-AIneutral
05/11/23 6:00 AMNasdaq : CMMB earningslow floatChemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate UpdateChemomab Therapeutics, Ltd.,, a...RHEA-AIneutral
04/26/23 7:00 AMNasdaq : CMMB conferenceslow floatChemomab Therapeutics to Present at 2023 Aegis Virtual ConferenceChemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the companyRHEA-AIneutral